酪氨酸激酶抑制剂诱发的甲状腺功能障碍：是误解还是确有其事？
Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
作者信息
Malhotra Anjli, Gupta Rajeev, Mahajan Shveta
机构信息
Department of Medicine, SGRD Institute of Medical Sciences and Research, Amritsar, Punjab, India.
Dental Surgeon, PHC Lakhanpur, Directorate of Health Services Jammu UT (J&K), India.
出版信息
Rep Pract Oncol Radiother. 2023 Aug 28;28(4):463-467. doi: 10.5603/RPOR.a2023.0055. eCollection 2023.
BACKGROUND
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder. It is associated with acquired genetic changes in the hematopoietic stem cells in the form of BCR-ABL fusion gene also known as Philadelphia chromosome.
MATERIALS AND METHODS
We prospectively studied thyroid function at baseline and at 6 months of imatinib treatment in 26 newly diagnosed BCR-ABL positive CML patients.
RESULT
The thyroid-stimulating hormone (TSH) levels increased significantly from baseline (3.20 ± 0.978 mIU/L . 3.724 ± 1.726 mIU/L, p < 0.05) after 6 months of treatment, 88.4% of the patients remained euthyroid. Only 2 patients had subclinical hypothyroidism, 1 had hypothyroidism after 6 months of tyrosine kinase inhibitors (TKI) therapy.
CONCLUSION
Imatinib did not have any significant effect on thyroid function in CML patients in this study.
背景
慢性粒细胞白血病（CML）是一种造血干细胞疾病。它与造血干细胞中获得性基因改变有关，表现为BCR-ABL融合基因，也称为费城染色体。
材料与方法
我们前瞻性地研究了26例新诊断的BCR-ABL阳性CML患者在基线时以及伊马替尼治疗6个月时的甲状腺功能。
结果
治疗6个月后，促甲状腺激素（TSH）水平从基线时的（3.20±0.978 mIU/L）显著升高至（3.724±1.726 mIU/L，p<0.05），88.4%的患者仍处于甲状腺功能正常状态。仅2例患者有亚临床甲状腺功能减退，1例在酪氨酸激酶抑制剂（TKI）治疗6个月后出现甲状腺功能减退。
结论
在本研究中，伊马替尼对CML患者的甲状腺功能没有显著影响。
Zotero 插件